Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

RheumMadness: An Educational Tournament

David L. Leverenz, MD, Akrithi Udupa, MD, Guy Katz, MD, Didem Saygin, MD, Christopher Witt, MD, Lisa G. Criscione-Schreiber, MD, MEd, & Matthew A. Sparks, MD  |  Issue: July 2021  |  July 15, 2021

Tasha Art; PureSolution / shutterstock.com

Tasha Art; PureSolution / shutterstock.com

RheumMadness is an online collaborative learning experience created to educate trainees, rheumatologists and the wider medical community about recent advances and important concepts in rheumatology. The project is funded by the Rheumatology Research Foundation Clinician Scholar Educator (CSE) Award and modeled after NephMadness, an educational initiative of the American Journal of Kidney Diseases (AJKD) that has engaged over a thousand nephrologists from all over the world.1-3

After a successful first year of RheumMadness, we are on course to create similar engagement in the rheumatology community, and we are thrilled to share our early experiences with this fun and educational activity.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In RheumMadness, rheumatology concepts are entered as teams to compete in a single-elimination tournament, much like basketball teams in the U.S. National Collegiate Athletic Association (NCAA) compete in the March Madness tourna­ment. The 16 teams in the 2021 Rheum­Madness bracket are recently published studies, such as avacopan for anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis and pre-inflammatory mesenchymal (PRIME) cells in rheuma­toid arthritis (see Figure 1). Participants submit their own bracket, in which they try to predict the winners of each match-up. The winners are then chosen by a Blue Ribbon Panel of rheumatology content experts.

Throughout this process, participants are invited to engage with a variety of social and educational elements designed to enable everyone who is crazy about rheuma­tology to connect, collaborate, compete and learn together.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Connect

Figure 1: The 2021 RheumMadness Bracket

Figure 1: The 2021 RheumMadness Bracket

RheumMadness is grounded in social constructivist learning theory, which proposes that deep and meaningful learning occurs when people build knowledge together through discussion, debate, shared experiences and other forms of social interaction.4 We all intuitively understand the value of social constructivism; it is the reason we have book clubs, interest groups and case-based discussions. Yet often, when we need to learn something new in medicine, we attend non-interactive lectures or scroll abstracts on PubMed alone. Even inter­active journal clubs at our own practices are limited by traditions and local pockets of expertise (or lack thereof), and we could all benefit from an increased diversity of perspectives on rheumatology topics.

With this in mind, RheumMadness is designed to build a community of learners online. Twitter is a lively forum for RheumMadness participants, with a total of 486 tweets from 105 users using the hashtag #RheumMadness during the 2021 tournament (see Figure 2). The impact of these tweets can be estimated by measuring

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:Education & Training Tagged with:online educationRheumMadness

Related Articles

    An Oral Targeted Therapy: RheumMadness 2022 Pim Kinases Scouting Report

    February 8, 2022

    According to research, Pim kinases contribute to the pathogenesis of rheumatoid arthritis (RA) and may have the therapeutic potential for inhibition in patients with RA.

    Conversation: RheumMadness 2022 Reproductive Health Guide Scouting Report

    March 2, 2022

    Rheumatologists play a critical role in the reproductive health of their patients, but only half of rheumatologists currently ask their patients about reproductive health or family planning issues. A new guideline seeks to change that.

    In the Bones: RheumMadness 2022 False Positive MRI in Axial SpA

    March 3, 2022

    Spondyloarthropathy (SpA) can be difficult to diagnose, with rheumatologists sometimes relying on classification criteria designed for clinical trials. Research examines how the use of MRIs affects the finding of bone marrow edema and the diagnosis of axial SpA.

    Beyond Trial & Error: RheumMadness 2022 AI: TNFi Response Scouting Report

    February 14, 2022

    As the capabilities of machine learning and artificial intelligence improve, rheumatologists have access to more data than ever, which may enable them to better predict which patients will respond to specific treatments, such as tumor necrosis factor inhibitors.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences